A cohort study found that nearly three fourths of infants received respiratory syncytial virus protection with either nirsevimab or through exposure to maternal RSVpreF in the 2023-2024 season.

Respiratory syncytial virus (RSV) (Fig. 1) causes a spectrum of respiratory illnesses in infants and young children that may lead to hospitalisations and a substantial number of outpatient visits ...

Respiratory syncytial virus (RSV) infections are the leading cause of viral death in infants, although RSV-related mortality has decreased since the development and approval of prophylactic ...

Health officials are urging older adults to get vaccinated against respiratory syncytial virus (RSV). NHS England announced ...

Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Pune, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus Therapeutics Market Size & Growth Analysis: “According to SNS Insider, The Respiratory Syncytial Virus (RSV) Therapeutics ...

As cold and flu season continues in Vermont, UVMMC is urging families to get their newborns and infants preventatively ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

Pregnant women across the Northern Territory now have free access to protection against a virus that is the leading cause of hospitalisation for babies. The federal government is investing $174.5m ...